A Comparative Bioavailability Study of Lomitapide 20 mg Intact vs Sprinkled

A Phase 1, Open-label, Randomised, Crossover Study to Determine the Comparative Bioavailability of 20 mg Lomitapide Where the Contents Have Been Opened and Sprinkled in Applesauce or Mashed Banana (Sprinkled Contents) to a Single Oral Capsule Dose of 20 mg Lomitapide (Intact Capsule) in Healthy Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02044419

Enrollment

Registered

2014-01-24

Start date

2013-10-30

Completion date

2013-12-23

Last updated

2018-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Comparative, Bioavailability, lomitapide

Brief summary

To compare the relative bioavailability of lomitapide when administered by sprinkling the contents of a 20 mg capsule of lomitapide in applesauce or in mashed banana to a single oral intact capsule dose of 20 mg lomitapide in healthy subjects.

Interventions

DRUGlomitapide

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

1. Subject is a non-smoking healthy male or female, aged between 18 and 40 years of age. 2. Subject has a BMI of 18.5 - 25 kg/m2. 3. Subject has total body weight between \> 50 kg to ≤ 100 kg. 4. Subjects must agree to use acceptable methods of contraception. 5. All females, regardless of childbearing potential, must have a negative serum beta human chorionic gonadotropin pregnancy test at Screening and on admission. 6. In good health, determined by no clinically significant or relevant abnormalities identified by a detailed medical history & full physical examination. 7. No known history of hypersensitivity or previous intolerance to lomitapide, applesauce, and/or banana. 8. Subjects must be capable of understanding and complying with the requirements of the protocol and must have signed the informed consent form prior to undergoing any study-related procedures.

Exclusion criteria

1. Subject has a clinically significant disease or any condition or disease that might affect drug absorption, distribution or excretion. 2. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs. 3. Any clinically significant abnormal laboratory, vital signs or other safety findings as determined by medical history, physical examination or other evaluations. 4. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator; 5. Electrocardiogram (ECG) abnormalities in the standard 12-lead ECG (at screening) such as a QTcF interval of \>450 msec, a history of a prolonged QTc interval or Brugada syndrome. 6. History or current evidence of any clinically relevant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrinological, allergic, dermatological, metabolic, neurological, psychiatric or other disease. 7. History or laboratory evidence of Gilbert's syndrome. 8. Positive results in any of the serology tests for Hepatitis B Surface Antigen (HbsAg), anti-Hepatitis core antibody (anti-HBc Ig G \[and anti-HBc IgM if IgG is positive\], Hepatitis C antibodies (anti-HCV), and HIV 1 and 2 antibodies, (anti-HIV 1/2). 9. Use of any drugs of abuse within 6 months prior to admission. 10. Confirmed positive results from urine drug screen (amphetamines, benzodiazepines, cocaine, cannabinoids, opiates, barbiturates and methadone) or from the alcohol breath test at screening and on admission (Day -1). 11. History or clinical evidence of alcohol or drug abuse within one year prior to admission. 12. Mentally handicapped. 13. Participation in a drug trial within 90 days prior to first drug administration. 14. Use of any prescription medication within 2 weeks prior to admission (Day -1), with the exception of the oral contraceptive pill. 15. Use of any substance inducing or inhibiting CYP3A4 enzymes within 30 days prior to admission (Day -1). 16. Use of any over-the-counter (OTC) medication (including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days prior to admission (Day -1), unless deemed acceptable by the Investigator and Sponsor. 17. Use of alcohol-, grapefruit-, starfruit-, or caffeine-containing foods or beverages within 72 hours prior to admission and through Study Completion. 18. Donation of more than 500 mL of blood within 90 days prior to drug administration. 19. Receipt of blood products within 2 months prior to admission. 20. Poor peripheral venous access. 21. Use of any tobacco- or nicotine-containing products within 6 months prior to admission (Day -1). 22. Any acute or chronic condition, scheduled hospitalisation (inclusive of elective surgery during study), or scheduled travel prior to completion of all study procedures. 23. Any circumstances or conditions, which, in the opinion of the PI, may affect full participation in the trial or compliance with the protocol. 24. Legal incapacity or limited legal capacity at screening. 25. Subjects who are vegetarians, vegans or have any dietary restrictions conflicting with the study standardised menus.

Design outcomes

Primary

Measure	Time frame	Description
AUC0-t	predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose	Area under the concentration-time curve from hour 0 to the last measurable concentration of lomitapide and its metabolites (M1& M3).
Cmax	predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose	Maximum observed concentration of lomitapide and its metabolites (M1& M3).
Tmax	predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose	Time to reach maximum plasma concentration of lomitapide and its metabolites (M1& M3).
t1/2	predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose	Terminal elimination half-life of lomitapide and its metabolites (M1& M3).
AUC0-∞	predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose	Area under the plasma concentration vs time curve from zero to infinity of lomitapide and its metabolites (M1& M3).
λz	predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours post-dose	Elimination rate constant estimated from individual linear regression of the terminal part of the log concentration vs time curve of lomitapide and its metabolites (M1& M3).

Countries

United Kingdom

Participant flow

Participants by arm

Arm	Count
Applesauce, Mashed Banana, Intact Capsule (ABC) Contents of single 20 mg capsule of lomitapide sprinkled in applesauce, mashed banana Capsule taken intact lomitapide	11
Mashed Banana, Intact Capsule, Applesauce (BCA) Contents of single 20 mg capsule of lomitapide sprinkled in applesauce& mashed banana Capsule taken intact lomitapide	10
Intact Capsule, Applesauce, Mashed Banana (CAB) Contents of single 20 mg capsule of lomitapide sprinkled in applesauce& mashed banana Capsule taken intact lomitapide	11
Total	32

Baseline characteristics

Characteristic	Applesauce, Mashed Banana, Intact Capsule (ABC)	Mashed Banana, Intact Capsule, Applesauce (BCA)	Intact Capsule, Applesauce, Mashed Banana (CAB)	Total
Age, Categorical <=18 years	0 Participants	0 Participants	0 Participants	0 Participants
Age, Categorical >=65 years	0 Participants	0 Participants	0 Participants	0 Participants
Age, Categorical Between 18 and 65 years	11 Participants	10 Participants	11 Participants	32 Participants
Age, Continuous	28.45 years STANDARD_DEVIATION 5.837	25.90 years STANDARD_DEVIATION 5.131	27.91 years STANDARD_DEVIATION 3.27	27.42 years STANDARD_DEVIATION 4.746
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants	0 Participants	1 Participants	1 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	11 Participants	10 Participants	10 Participants	31 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	1 Participants	1 Participants	1 Participants	3 Participants
Race (NIH/OMB) Black or African American	3 Participants	2 Participants	4 Participants	9 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	1 Participants	1 Participants	2 Participants
Race (NIH/OMB) White	7 Participants	6 Participants	5 Participants	18 Participants
Region of Enrollment United Kingdom	11 participants	10 participants	11 participants	32 participants
Sex: Female, Male Female	3 Participants	6 Participants	6 Participants	15 Participants
Sex: Female, Male Male	8 Participants	4 Participants	5 Participants	17 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk
deaths Total, all-cause mortality	0 / 30	0 / 31	0 / 31
other Total, other adverse events	5 / 30	6 / 31	6 / 31
serious Total, serious adverse events	0 / 30	0 / 31	0 / 31

Outcome results

Primary

AUC0-∞

Area under the plasma concentration vs time curve from zero to infinity of lomitapide and its metabolites (M1& M3).